Docket No. ARS-122 Serial No. 10/570.122

In the Claims

2

1-45 (canceled).

- 46 (new). A method for treating a fibrotic disease comprising administering to a patient in need thereof an effective amount of a composition comprising a pharmaceutically acceptable carrier and:
 - 1) polypeptide is selected from the group consisting of:
 - a) SEQ ID NO: 2, 5, 7 or 10;
 - b) SEQ ID NO: 3, 6, 8 or 11:
 - c) a polypeptide comprising SEQ ID NO: 2, 3, 5, 6, 7, 8, 10 or 11; and
 - a polypeptide that has at least 90% identity to a polypeptide of (a) to (c) and inhibits TNF-related apoptosis-inducing ligand/Apo2 ligand (TRAIL).
- 47 (new). The method according to claim 46, wherein the fibrotic disease is a connective tissue disease, lung fibrosis or liver fibrosis.
- 48 (new). The method according to claim 46, wherein the polypeptide is glycosylated at one or more sites.
- 49 (new). The method according to claim 46, wherein the polypeptide comprising SEQ ID NO: 2 or SEQ ID NO: 3 is a fusion protein.
- 50 (new). The method according to claim 49, wherein the fusion protein comprises an immunoglobulin Fc region fused to SEQ ID NO: 2 or SEQ ID NO: 3.
- 51 (new). The method according to claim 46, wherein the polypeptide has at least 90% identity to SEQ ID NO: 2 or SEQ ID NO: 3 and inhibits TNF-related apoptosis-inducing ligand/Apo2 ligand (TRAIL) and is a fusion protein.

3 Docket No. ARS-122 Serial No. 10/570,122

52 (new). The method according to claim 51, wherein the fusion protein comprises an immunoglobulin Fc region fused to the polypeptide that has at least 90% identity to SEQ ID NO: 2 or SEQ ID NO: 3.

53 (new). The method according to claim 46, wherein the polypeptide comprises SEQ ID NO: 2.

54 (new). $${\rm The}$$ method according to claim 46, wherein the polypeptide comprises SEQ ID NO: 3.

55 (new). The method according to claim 46, wherein the polypeptide consists of SEQ ID NO: 2.

56 (new). $${\rm The}$$ method according to claim 46, wherein the polypeptide consists of SEQ ID NO: 3.

 $\label{eq:proposition} 57 \, (\text{new}). \qquad \text{The method according to claim 46, wherein the composition further comprises} \\ \text{an interferon.}$

58 (new). The method according to claim 57, wherein the interferon is interferon-β.

59 (new). The method according to claim 46, wherein a composition comprising an interferon is administered to said patient simultaneously, sequentially, or separately.